Case report: Successful treatment of hyperbaric oxygen for radiation-induced hemorrhagic cystitis in a 95-year-old patient with bladder cancer.

IF 3.5 3区 医学 Q2 ONCOLOGY Frontiers in Oncology Pub Date : 2025-02-03 eCollection Date: 2025-01-01 DOI:10.3389/fonc.2025.1410148
Li Lin, Man He, Yanyan Zeng, Xiaoxiao Ni, Yequn Guo, Xiaojuan Xie, Lingling Sun, Huai Huang
{"title":"Case report: Successful treatment of hyperbaric oxygen for radiation-induced hemorrhagic cystitis in a 95-year-old patient with bladder cancer.","authors":"Li Lin, Man He, Yanyan Zeng, Xiaoxiao Ni, Yequn Guo, Xiaojuan Xie, Lingling Sun, Huai Huang","doi":"10.3389/fonc.2025.1410148","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Severe radiation-induced hemorrhagic cystitis (RHC) may ultimately require radical cystectomy. High-quality clinical evidence exists regarding the impact of hyperbaric oxygen therapy (HBOT) on RHC. However, there is a lack of reported data addressing the applicability of HBOT in very elderly patients (over 90 years old) with severe bleeding necessitating multiple blood transfusions.</p><p><strong>Case presentation: </strong>The patient is a 95-year-old male who suffered from severe hematuria due to RHC after 33 sessions of radiotherapy for muscle-invasive bladder cancer (T2N0M0, stage: II). After a series of subsequent therapies that failed to control the hematuria, the patient received 196 HBOTs between 11 October 2022 and 23 October 2023. Following a progressively adjusted HBOT protocol, the patient's hematuria (urine red blood cell (RBC) count showed 210,859 RBC/μL at maximum) was effectively controlled, and his symptoms subsequently resolved after 69 HBOTs. After the 196th HBOT, pelvic MRI revealed a reduction in the size of the lesion on the left posterior wall of the bladder compared to prior assessments. This reduction was suggestive of diminished intravesical hematoma. As of 26 October 2023, it is noteworthy that the patient's hemoglobin level has restored to the pre-hematuria level (106 g/L) with no need for blood transfusions for 8 consecutive months. Moreover, there was no recurrence of hematuria during the follow-up period. To the best of our knowledge, this report represents the first documented case of hematuria resolution in a patient over 90 years old with severe RHC.</p><p><strong>Conclusion: </strong>This case represents the first documented instance of successful hematuria resolution in a patient over 90 years of age with severe RHC. The positive therapeutic outcome achieved with personal protocol (1.4-1.6 ATA) in this 95-year-old patient, expands hyperbaric oxygen pressure options for elderly patients. Moreover, it also records a comprehensive dataset, including the time of the patient's recurrence of hematuria and the subsequent trend of hematuria control, which contributes valuable evidence to the research on HBOT for the repair of bladder mucosal tissue.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1410148"},"PeriodicalIF":3.5000,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11830598/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fonc.2025.1410148","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Severe radiation-induced hemorrhagic cystitis (RHC) may ultimately require radical cystectomy. High-quality clinical evidence exists regarding the impact of hyperbaric oxygen therapy (HBOT) on RHC. However, there is a lack of reported data addressing the applicability of HBOT in very elderly patients (over 90 years old) with severe bleeding necessitating multiple blood transfusions.

Case presentation: The patient is a 95-year-old male who suffered from severe hematuria due to RHC after 33 sessions of radiotherapy for muscle-invasive bladder cancer (T2N0M0, stage: II). After a series of subsequent therapies that failed to control the hematuria, the patient received 196 HBOTs between 11 October 2022 and 23 October 2023. Following a progressively adjusted HBOT protocol, the patient's hematuria (urine red blood cell (RBC) count showed 210,859 RBC/μL at maximum) was effectively controlled, and his symptoms subsequently resolved after 69 HBOTs. After the 196th HBOT, pelvic MRI revealed a reduction in the size of the lesion on the left posterior wall of the bladder compared to prior assessments. This reduction was suggestive of diminished intravesical hematoma. As of 26 October 2023, it is noteworthy that the patient's hemoglobin level has restored to the pre-hematuria level (106 g/L) with no need for blood transfusions for 8 consecutive months. Moreover, there was no recurrence of hematuria during the follow-up period. To the best of our knowledge, this report represents the first documented case of hematuria resolution in a patient over 90 years old with severe RHC.

Conclusion: This case represents the first documented instance of successful hematuria resolution in a patient over 90 years of age with severe RHC. The positive therapeutic outcome achieved with personal protocol (1.4-1.6 ATA) in this 95-year-old patient, expands hyperbaric oxygen pressure options for elderly patients. Moreover, it also records a comprehensive dataset, including the time of the patient's recurrence of hematuria and the subsequent trend of hematuria control, which contributes valuable evidence to the research on HBOT for the repair of bladder mucosal tissue.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
病例报告:高压氧治疗95岁膀胱癌患者放射性出血性膀胱炎成功。
背景:严重放射性出血性膀胱炎(RHC)最终可能需要根治性膀胱切除术。关于高压氧治疗(HBOT)对RHC的影响,存在高质量的临床证据。然而,缺乏关于HBOT在高龄严重出血需要多次输血的患者(90岁以上)中的适用性的报道数据。病例介绍:患者为95岁男性,肌肉浸润性膀胱癌(T2N0M0期,II期)放疗33次后,因RHC出现严重血尿。在一系列后续治疗未能控制血尿后,患者于2022年10月11日至2023年10月23日期间接受了196次HBOTs。逐步调整HBOT方案后,患者血尿(尿红细胞(RBC)计数最高为210,859 RBC/μL)得到有效控制,经69次HBOT治疗后症状消失。第196次HBOT手术后,盆腔MRI显示膀胱左后壁病变面积较先前评估减小。这种减少提示膀胱内血肿减少。截至2023年10月26日,值得注意的是,患者血红蛋白水平已恢复到血尿前水平(106 g/L),连续8个月无需输血。随访期间无血尿复发。据我们所知,这是第一例90岁以上严重RHC患者血尿缓解的病例。结论:该病例是第一例90岁以上严重RHC患者成功解决血尿的病例。在这位95岁的患者中,个人方案(1.4-1.6 ATA)取得了积极的治疗结果,扩大了老年患者的高压氧压力选择。此外,它还记录了一个全面的数据集,包括患者血尿复发的时间和随后的血尿控制趋势,这为HBOT用于膀胱粘膜组织修复的研究提供了有价值的证据。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Frontiers in Oncology
Frontiers in Oncology Biochemistry, Genetics and Molecular Biology-Cancer Research
CiteScore
6.20
自引率
10.60%
发文量
6641
审稿时长
14 weeks
期刊介绍: Cancer Imaging and Diagnosis is dedicated to the publication of results from clinical and research studies applied to cancer diagnosis and treatment. The section aims to publish studies from the entire field of cancer imaging: results from routine use of clinical imaging in both radiology and nuclear medicine, results from clinical trials, experimental molecular imaging in humans and small animals, research on new contrast agents in CT, MRI, ultrasound, publication of new technical applications and processing algorithms to improve the standardization of quantitative imaging and image guided interventions for the diagnosis and treatment of cancer.
期刊最新文献
Correction: High-intensity focused ultrasound as a combined approach for the treatment of recurrent low-grade endometrial stromal sarcoma: a case report and literature review. Endocrine regimen and early subclinical atherosclerosis in premenopausal HR+/HER2- breast cancer: real-world evidence and regimen-dependent effects of Sanhuang Decoction. Gastric mucinous adenocarcinoma presenting with chronic cough, bronchovascular bundle thickening, and multiple pulmonary nodules: a case report. Heterogeneity in benefit finding among breast cancer patients: a latent profile analysis and influencing factors. Shox2 and Rassf1a DNA methylation: diagnostic utility and association with clinical stage, histological progression and gene mutational landscape in lung adenocarcinoma.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1